Postmenopausal hormone replacement therapy and breast cancer

Area of Science:

• Endocrinology
• Epidemiology
• Tumor Cell Biology

Background:

• 17beta-estradiol, a natural hormone, is a weak genotoxic and mutagenic carcinogen.
• This genotoxicity provides a biological basis for concerns linking hormone replacement therapy (HRT) to breast cancer.
• Epidemiological studies are complex due to small effect sizes and confounding factors.

Purpose of the Study:

• To review the current understanding of the association between postmenopausal hormone replacement therapy (HRT) and breast cancer risk.
• To discuss the factors influencing this risk and clinical implications.

Main Methods:

• Review of epidemiological, endocrinological, and tumor cell biology research.
• Analysis of data concerning HRT duration, dosage, and individual risk factors.

Main Results:

• Long-term HRT use (>10 years) is associated with an increased risk of breast cancer.
• This risk is comparable to the risk from delaying menopause for the same duration.
• Individual risk is influenced by HRT exposure (duration, dose) and predisposing genetic and environmental factors.

Conclusions:

• The consensus indicates a link between long-term HRT and elevated breast cancer risk.
• Clinical practice should involve using the lowest effective HRT dosage.
• For women with severe estrogen deficiency symptoms and a history of breast cancer, low-dose estrogen combined with a selective estrogen receptor modulator may be a viable treatment option.